Literature DB >> 12448269

[Which antihypertensive drugs should be used in the primary prevention of cardiovascular disease?].

Atle Fretheim1, Arild Bjørndal, Andrew D Oxman, Audun Dyrdal, Michael Golding, Leiv Ose, Asmund Reikvam, Per Teisberg.   

Abstract

BACKGROUND: Several clinical practice guidelines for the treatment of hypertension are available. The quality of these guidelines varies and the basis for their conclusions is often not clear. We have used systematic and explicit methods in the development of a new set of recommendations. This is the second of three articles describing these guidelines.
MATERIAL AND METHODS: Evidence was found by a systematic search in databases and reference lists in guidelines and articles. A set of recommendations was prepared based on a critical appraisal of the literature. These were revised through discussions with a panel of physicians, and agreed upon after several iterations. The guidelines were circulated to professional, governmental and patient organisations. RESULTS AND
INTERPRETATION: Thiazides should be first-choice drugs for the treatment of uncomplicated hypertension. Beta-blockers are a reasonable second choice. The treatment goal should be below 140/90 mm Hg. For combination therapy, thiazides and beta-blockers should be first choice. Diabetic patients should be treated aggressively with a diastolic blood pressure goal below 80 mm Hg. Angiotensin-II antagonists or angiotensin converting enzyme-inhibitors should be first choice drugs for diabetics with microalbuminuria. Patients with hypercholesterolaemia are not given a particular recommendation for choice of drug. Patients with asthma or chronic obstructive pulmonary disease should choose other drugs than beta-blockers. Thiazides should be avoided if the patient has, or has had, gout.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12448269

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  4 in total

1.  Rational prescribing in primary care (RaPP): a cluster randomized trial of a tailored intervention.

Authors:  Atle Fretheim; Andrew D Oxman; Kari Håvelsrud; Shaun Treweek; Doris T Kristoffersen; Arild Bjørndal
Journal:  PLoS Med       Date:  2006-06       Impact factor: 11.069

2.  Rational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230].

Authors:  Atle Fretheim; Andrew D Oxman; Shaun Treweek; Arild Bjørndal
Journal:  BMC Health Serv Res       Date:  2003-02-27       Impact factor: 2.655

3.  The potential of electronic medical record systems to support quality improvement work and research in Norwegian general practice.

Authors:  Shaun Treweek
Journal:  BMC Health Serv Res       Date:  2003-06-06       Impact factor: 2.655

4.  Improving prescribing of antihypertensive and cholesterol-lowering drugs: a method for identifying and addressing barriers to change.

Authors:  Atle Fretheim; Andrew D Oxman; Signe Flottorp
Journal:  BMC Health Serv Res       Date:  2004-09-03       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.